(Q54322781)

27 May 2018

title

Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer. (English)

1 reference

27 May 2018

author name string

Hongyan Ying

1

1 reference

27 May 2018

Xian-Da Yang

2

1 reference

27 May 2018

Zhao Sun

3

1 reference

27 May 2018

Xiaohong Ning

4

1 reference

27 May 2018

Yingyi Wang

5

1 reference

27 May 2018

Chunmai Bai

6

1 reference

27 May 2018

Shuchang Chen

7

1 reference

27 May 2018

Yuzhou Wang

8

1 reference

27 May 2018

publication date

13 September 2014

1 reference

27 May 2018

published in

Medical Oncology

1 reference

27 May 2018

volume

31

1 reference

27 May 2018

issue

10

1 reference

27 May 2018

page(s)

220

1 reference

27 May 2018

cites work

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Lung cancer in never smokers: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

The impact of sex and smoking status on the mutational spectrum of epidermal growth factor receptor gene in non small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Genomic landscape of non-small cell lung cancer in smokers and never-smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Occupational exposure to carcinogens and risk of lung cancer: results from The Netherlands cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Genotype-driven therapies for non-small cell lung cancer: focus on EGFR, KRAS and ALK gene abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Acquired Resistance to Crizotinib from a Mutation in CD74 – ROS1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Familial risk of lung cancer among nonsmokers and their relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Wood-smoke exposure as a response and survival predictor in erlotinib-treated non-small cell lung cancer patients: an open label phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Wood dust exposure and the association with lung cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12032-014-0220-4

Indoor air pollution in developing countries: a major environmental and public health challenge.

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25216867

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S12032-014-0220-4

1 reference

27 May 2018

1 reference

27 May 2018